Relmada Therapeutics Inc ( (RLMD) ) has released its Q1 earnings. Here is a breakdown of the information Relmada Therapeutics Inc presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system diseases and other disorders, with a particular emphasis on NDV-01 and Sepranolone. In its latest earnings report for the quarter ending March 31, 2025, Relmada Therapeutics Inc. reported a net loss of $17.6 million, a decrease from the $21.8 million loss in the same period last year. The company’s operating expenses were reduced to $18.2 million from $23 million, primarily due to lower research and development and general administrative costs. Despite the losses, the company maintained a strong cash position with $25.9 million in short-term investments. Relmada has been actively pursuing strategic partnerships, including an exclusive license agreement with Trigone for NDV-01 and an asset purchase agreement with Asarina Pharma for Sepranolone. The company faces challenges such as a Nasdaq compliance issue regarding its stock price and ongoing liquidity concerns. Looking ahead, Relmada’s management remains focused on advancing its clinical programs and securing additional financing to support its operations and strategic initiatives.